Beware of SBET, WeBull, and Sarepta
Investors who bought WeBull (BULL) before last week gained 33.6%. However, after the market closed on Friday, July 18, the trading firm filed for a massive stock sale.WeBull is selling 75,159,236 shares, or one-quarter of its entire float, by a selling shareholder. BULL stock traded as low as $9.54 and as high as $79.56. It closed at $16.89 last week.Investors should consider Coinbase (COIN), Robinhood (HOOD), or Futu (FUTU) instead.The jump and fade cycle in SharpLink Gaming (SBET) will benefit day traders. However, investors should avoid it entirely. The stock rose after the online performance marketing platform briefly became the biggest holder of ether (ETH-USD). According to strategicethreserve.xyz, the top three holders are Bitmine Immersion Tech, SharpLink, and Ethereum Foundation.In the biotechnology sector, Sarepta Therapeutics (SRPT) lost 36% of its value last Friday. The company reported a third death associated with the DMD gene therapy. It is down by 88.4% YTD. Bloomberg’s report that the FDA commissioner, Marty Makary, might be “taking a hard look” at halting shipments of the gene therapy.Sarepta co-developed the therapy with Roche (RHHBY).The casualty sets back the use of AAV vectors for delivering gene therapy. This might lead to Sarepta shifting toward siRNA. That would increase risks, adding uncertainty to Sarepta’s gene therapy platform.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


